Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02549742
Other study ID # HH1222
Secondary ID
Status Recruiting
Phase Phase 2
First received September 6, 2015
Last updated January 17, 2017
Start date February 2014
Est. completion date September 2019

Study information

Verified date January 2017
Source Rigshospitalet, Denmark
Contact Christina C. Plaschke, MD
Phone +45 29 25 92 45
Email caroline@dadlnet.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A phase II clinical trial testing electrochemotherapy on mucosal recurrent head and neck cancer. Twenty-five patients will be treated. Primary outcome is tumour response on imaging. Secondary outcomes are response from tissue samples, VAS score, Quality of life evaluation and side effects to treatment.


Description:

Electric pulses may be used to transiently permeabilise cell membranes, enabling passage of otherwise non-permeating molecules. This dramatically enhances the cytotoxic effect of certain chemotherapeutic agents, and is termed electrochemotherapy. Electrochemotherapy is now standardly used in the treatment of cutaneous metastases of various cancers in over 100 cancer centers around Europe.

The intention of this trial is to investigate the possible use of electrochemotherapy in recurrent head and neck cancer as a palliative treatment. Surgery and radiotherapy, with the possible addition of chemotherapy, cures a large part of patients with head and neck cancer. However, in the event of recurrence curative options may be exhausted and the patient is referred for palliative chemotherapy.

It is for this patient group, the investigators propose electrochemotherapy in a clinical trial.

The electrochemotherapy is administered as a once-only treatment, with possible retreatment after eight weeks. Under general anesthesia, chemotherapy is administered intravenously, followed by application of electric pulses to the tumour area. Before treatment, the location and spread of the tumour is determined by imaging.

The trial includes evaluation of response by MRI (magnetic resonance imaging) and PET/CT (Positron Emission Tomography - Computed Tomography) scans (base-line, 4 weeks, 8 weeks), tissue samples, as well as adverse events registration and questionnaires on quality of life. The planned study is a phase II clinical study, prospective, observational with up to 25 patients.

Treatments will be performed in collaboration between the Department of Oncology, Copenhagen University Hospital Herlev, which has extensive experience in electrochemotherapy, and the Department of Ear Nose and Throat Surgery at Copenhagen University Hospital Rigshospitalet, that has the surgical expertise and set-up needed.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date September 2019
Est. primary completion date September 2019
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. Subject age > 18 years.

2. Verified cancer of the head and neck area of any histology.

3. At least one tumour lesion should be accessible for electroporation.

4. Performance status WHO <= 2nd

5. Progressive and / or metastatic disease.

6. Expected survival of > 3 months.

7. Measurable disease is defined as at least one measurable lesion by RECIST 1.1.

8. A treatment-free interval of more than 4 weeks since chemotherapy or radiation therapy.

9. The participant should have been offered the current standard treatment. If there are no further standard treatment to offer or if the participant does not want to receive this, the participant may be included in the trial.

10. The participant should be able to understand the information for participants and be willing and able to comply with hospitalization in the treatment and the agreed follow-up visits and tests.

11. Platelets = 50 billion / L, INR (international normalized ratio) > 1.5. Medical correction is permitted, e.g. correction using vitamin K.

12. Sexually active women who can become pregnant should use adequate contraception during this trial and 6 months after administration of bleomycin (pill, spiral, injection of prolonged progestin subdermal implantation, hormone-containing vaginal devices, transdermal patches).

13. Signed informed consent. -

Exclusion Criteria:

Participants should be excluded if they meet just one of the criteria stated below.

1. Symptomatic progression of the participants cancerous disease that requires another intervention.

2. Acute lung infection

3. Symptoms of lung function impairment. This triggers a lung function test (DLCO = diffusing capacity of the lungs for carbon monoxide), if moderate to severe the participant will be excluded.

4. Previous bleomycin treatment with cumulative dose more than 240,000 Units / m2.

5. History of severe allergic reactions associated with bleomycin.

6. Allergy to constituents of the planned anesthetic.

7. Coagulation disorder which can not be corrected.

8. Chronic renal dysfunction with creatinine> 150 micromoles / liter, will trigger a Cr-51-EDTA (Chromium-51-ethylenediamine tetra acetic acid) clearance. If this is too impaired, the participant is excluded.

9. Pregnancy or lactation.

10. While participation in other clinical trials involving experimental drugs or involved in a trial within 4 weeks prior to study drug administration.

11. Other disorders investigator finds incompatible with participation in the trial. -

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Electrochemotherapy
Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
Device:
Cliniporator
Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
Drug:
Bleomycin
Administered intravenously or injected into the tumour before electroporation.

Locations

Country Name City State
Denmark Department of Otorhinolaryngology, Rigshospitalet, Copenhagen University Hospital Copenhagen

Sponsors (2)

Lead Sponsor Collaborator
Rigshospitalet, Denmark Copenhagen University Hospital at Herlev

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Tumour response from PET/CT scans (Positron Emission Tomography - Computed Tomography) 8 weeks after treatment
Secondary Tumour response from MRI scans (Magnetic resonance imaging) 8 weeks after treatment
Secondary Tumour response from tissue samples Still cancer activity or not 4 weeks after treatment
Secondary VAS score (Visual Analogue Scale) Participant assessed baseline, 4 weeks and 8 weeks after treatment
Secondary Quality of life EORTC scores for head and neck (The European Organisation for Research and Treatment of Cancer) baseline, 4 weeks and 8 weeks after treatment
Secondary CTCAE recordings (Common Terminology Criteria for Adverse Events) side effects scored by CTCAE version 4.0 baseline, 4 weeks and 8 weeks after treatment
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04566367 - Blue Laser Imaging (BLI) for Detection of Secondary Head and Neck Cancer N/A
Terminated NCT02521870 - A Trial of Intratumoral Injections of SD-101 in Combination With Pembrolizumab in Patients With Metastatic Melanoma or Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT05572684 - A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT02268344 - Brief Intraoperative Electrical Stimulation for Prevention of Shoulder Dysfunction After Oncologic Neck Dissection N/A
Terminated NCT00198328 - Medpulser Electroporation With Bleomycin Study to Treat Posterior Head and Neck Squamous Cell Carcinoma Phase 3
Recruiting NCT04858269 - First Line Weekly Chemo/Immunotherapy for Metastatic Head/Neck Squamous Cell Carcinoma Patients Phase 2
Recruiting NCT05878964 - Evaluation of Skin Health and QoL in Pts Receiving Anti-PD1/PDL1/CTLA4 or CDK Inhibitors.
Recruiting NCT03051269 - Calcium Electroporation for Head and Neck Cancer Phase 1
Completed NCT05833841 - Swallowing Function in Patients With Head and Neck Cancers N/A
Withdrawn NCT03747562 - Study of Efficacy and Safety of Gabapentin to Reduce the Need for Strong Opioid Use in Head and Neck Cancer Patients. Phase 3
Completed NCT03572829 - Aprepitant for Nause and Vomiting Induced by Chemoradiotherapy in HNSCC Phase 2
Completed NCT02075385 - Swallowing Intervention During Radiochemotherapy on Head and Neck Cancer Phase 2
Completed NCT01951664 - Feasibility and Preliminary Efficacy of Hatha Yoga in Head and Neck Cancer Survivors N/A
Recruiting NCT05838729 - Study of RiMO-301 and Radiotherapy With PD-1 Inhibitor for the Treatment of Head-Neck Cancer Phase 1/Phase 2
Completed NCT03832686 - Investigation of Two Swallowing Therapy Models During Radiation Therapy for Head and Neck Cancer N/A
Recruiting NCT05382585 - Newer Therapeutic Targets in Head and Neck Cancers